ATE183927T1 - Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoff - Google Patents

Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoff

Info

Publication number
ATE183927T1
ATE183927T1 AT93901816T AT93901816T ATE183927T1 AT E183927 T1 ATE183927 T1 AT E183927T1 AT 93901816 T AT93901816 T AT 93901816T AT 93901816 T AT93901816 T AT 93901816T AT E183927 T1 ATE183927 T1 AT E183927T1
Authority
AT
Austria
Prior art keywords
active ingredient
gel matrix
matrix containing
polysaccharide
immobilized active
Prior art date
Application number
AT93901816T
Other languages
English (en)
Inventor
Margaret Joan Taylor
Original Assignee
Univ Montfort
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montfort filed Critical Univ Montfort
Application granted granted Critical
Publication of ATE183927T1 publication Critical patent/ATE183927T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT93901816T 1992-01-10 1993-01-08 Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoff ATE183927T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929200638A GB9200638D0 (en) 1992-01-10 1992-01-10 Drug system

Publications (1)

Publication Number Publication Date
ATE183927T1 true ATE183927T1 (de) 1999-09-15

Family

ID=10708507

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93901816T ATE183927T1 (de) 1992-01-10 1993-01-08 Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoff

Country Status (11)

Country Link
US (2) US5830506A (de)
EP (1) EP0626862B1 (de)
JP (1) JP4025363B2 (de)
AT (1) ATE183927T1 (de)
AU (1) AU3263093A (de)
DE (1) DE69326234T2 (de)
DK (1) DK0626862T3 (de)
ES (1) ES2135458T3 (de)
GB (1) GB9200638D0 (de)
GR (1) GR3031479T3 (de)
WO (1) WO1993013803A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200638D0 (en) * 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
GB9313484D0 (en) 1993-06-30 1993-08-11 Univ Montfort Drug system ii
GB9805896D0 (en) 1998-03-20 1998-05-13 Eglise David Remote analysis system
EP1212601A4 (de) * 1999-08-27 2006-03-29 Biotech Inc M Glukosebiosensor
JP2004507283A (ja) * 2000-04-22 2004-03-11 エム−バイオテック インコーポレイテッド ヒドロゲルのバイオセンサとバイオセンサに基づいた健康のアラームシステム(hydrogelbiosensorandbiosensor−basedhealthalarmsystem)
GB0116860D0 (en) * 2001-07-10 2001-09-05 Univ Montfort Gel compositions
EP1418876A4 (de) 2001-08-17 2007-07-11 Univ Pittsburgh Verabreichung von östradiol-metaboliten zur behandlung oder prävention von adipositas, des metabolischen syndroms, von diabetes und von gefäss- und nierenerkrankungen
US6943267B1 (en) 2001-08-24 2005-09-13 Utah State University Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases
US20080279936A1 (en) * 2001-10-10 2008-11-13 The University Of Pittsburgh Estradiol metabolites for reduction of endothelin production
US20090118605A1 (en) * 2002-08-30 2009-05-07 Northwestern University Surface-enhanced raman nanobiosensor
CA2509382A1 (en) 2002-12-17 2004-07-08 Todd C. Zion Stimuli-responsive systems for controlled drug delivery
KR20050104383A (ko) * 2003-02-20 2005-11-02 유니버시티 오브 피츠버그 폐 고혈압의 치료를 위한 에스트라디올 대사물
US20060194775A1 (en) * 2003-02-20 2006-08-31 University Of Pittsburgh Estradiol metabolites for the treatment of pulmonary hypertension
US7806856B2 (en) * 2005-04-22 2010-10-05 Accessclosure, Inc. Apparatus and method for temporary hemostasis
US7687608B2 (en) 2005-10-19 2010-03-30 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
WO2010088268A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
WO2010088300A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Crystalline insulin-conjugates
US8623345B2 (en) 2009-03-20 2014-01-07 Smartcells Terminally-functionalized conjugates and uses thereof
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
EP2598522A4 (de) 2010-07-28 2014-11-12 Smartcells Inc Rekombinante lektine, bindungsstellenmodifizierte lektine und anwendungen davon
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
GB201314640D0 (en) 2013-08-15 2013-10-02 Univ Montfort Matrix gel
KR20160065930A (ko) 2013-10-04 2016-06-09 머크 샤프 앤드 돔 코포레이션 글루코스-반응성 인슐린 접합체
WO2018175272A1 (en) 2017-03-23 2018-09-27 Merck Sharp & Dohme Corp. Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes
EP3727424A4 (de) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. Konjugatbasierte systeme für kontrollierte insulinfreisetzung
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
CN114432243B (zh) * 2022-01-20 2023-08-29 华南师范大学 一种响应pH和葡萄糖的纳米载体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348387A (en) * 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
HK1002252A1 (en) * 1991-04-02 1998-08-07 Biotech Australia Pty. Limited Oral delivery systems for microparticles
GB9200638D0 (en) * 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
GB9313484D0 (en) * 1993-06-30 1993-08-11 Univ Montfort Drug system ii

Also Published As

Publication number Publication date
GR3031479T3 (en) 2000-01-31
JP4025363B2 (ja) 2007-12-19
US20020168409A1 (en) 2002-11-14
ES2135458T3 (es) 1999-11-01
DK0626862T3 (da) 1999-12-13
EP0626862A1 (de) 1994-12-07
GB9200638D0 (en) 1992-03-11
WO1993013803A1 (en) 1993-07-22
US7063863B2 (en) 2006-06-20
AU3263093A (en) 1993-08-03
EP0626862B1 (de) 1999-09-01
DE69326234D1 (de) 1999-10-07
JPH07507268A (ja) 1995-08-10
US5830506A (en) 1998-11-03
DE69326234T2 (de) 1999-12-30

Similar Documents

Publication Publication Date Title
ATE183927T1 (de) Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoff
AU628674B2 (en) Polymer complexes of a sugar response type
Sethi et al. Study of a cross-linked hydrogel of Karaya gum and Starch as a controlled drug delivery system
Singh et al. Biomedical applications of chitin, chitosan, and their derivatives
US5902607A (en) Reversible cross-linked gel
Bhardwaj et al. Natural gums and modified natural gums as sustained-release carriers
Gliko-Kabir et al. Low swelling, crosslinked guar and its potential use as colon-specific drug carrier
Kim et al. Refined control of thermoresponsive swelling/deswelling and drug release properties of poly (N-isopropylacrylamide) hydrogels using hydrophilic polymer crosslinkers
KR880010769A (ko) 안정한 안과용 수성 조성물 및 그 제조방법
ES2093625T3 (es) Administracion extendida de farmaco de moleculas pequeñas solubles en agua.
Liao et al. Temperature/pH dual sensitive Hericium erinaceus residue carboxymethyl chitin/poly (N-isopropyl acrylamide) sequential IPN hydrogels
GB1283857A (en) Size for glass fibres
CA2067228A1 (en) Drug delivery system, method for preparing the same and use thereof
Verestiuc et al. Functionalized chitosan/NIPAM (HEMA) hybrid polymer networks as inserts for ocular drug delivery: Synthesis, in vitro assessment, and in vivo evaluation
KR920002155A (ko) 슈크랄페이트(Sucralfate) 저작성 타블렛
JP3647859B2 (ja) 酵素的に制御された薬剤放出のための架橋されたポリヒドロキシ材料
KR950031053A (ko) 이온성 고분자 네트웍을 갖는 피부약물전달체계
Landale et al. Characterization by affinity electrophoresis of an alpha-1, 6-glucan-binding protein from Streptococcus sobrinus
US4379038A (en) Process for preparing a physiologically active substance controlled release composite composition
JPH06100468A (ja) 徐放性組成物
Viyoch et al. Development of hydrogel patch for controlled release of alpha‐hydroxy acid contained in tamarind fruit pulp extract
US5215752A (en) Pharmaceutical tablets and capsule granulates of scleroglucan and active substance
EP0333105B1 (de) Scleroglucan und Wirkstoff enthaltende pharmazeutische Tabletten und Kapselgranulate
Jawad A Review On Novel Approach Of Drug Delivery–Hydrogels
Kaczmarek-Szczepańska Dual-cross-linked nanocomposite hydrogels for potential antibacterial applications

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee